New Scientist4h
Mpox became a global health emergency for the second time in 2024
Surging mpox cases in East, West and Central Africa prompted the World Health Organization to once again make the infection a ...
FiercePharma1d
Siga's smallpox antiviral Tpoxx misses the mark in another mpox study
It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug ...
Siga's mpox drug did not improve lesion resolution or pain, NIH study finds
Siga Technologies' antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among ...
Rutgers University2d
Mpox Vaccination Rates Highest Among Cisgender Sexual Minority Men
As a second wave of the viral disease looms, Rutgers Health researchers call for more studies on long-term immunity.
pharmaphorum1d
NIH abandons trial of SIGA's mpox drug
As a result of the preliminary STOMP data – which gave the chances of a positive outcome from the study at less than 1% – the ...
Chambersburg Public Opinion on MSN11d
Take Care: Mpox is a global health emergency. Here's what you need to know.
Keystone Health shares key information about mpox, a cousin of smallpox that WHO has declared a global public health ...
Morocco produces Africa’s first mpox tests as the continent tries to rely less on imports
After African countries struggled to get testing kits during the COVID-19 pandemic, officials vowed to make the continent ...
Survey shows Mpox vaccination rates highest among cisgender sexual minority men
A Rutgers Health survey of LGBTQ+ individuals in New York and New Jersey reveals that cisgender men, gay individuals and full ...
cidrap.umn1d
Trial stops enrollment after Tpoxx fails to speed clade 2 mpox healing or pain relief
STOMP is a randomized, controlled, double-blind trial to evaluate the safety and effectiveness of Tpoxx for treating mpox. In ...